Sageworth Trust’s GSK GSK Stock Holding History

Sageworth Trust’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-245	Closed	-$8.72K	–	227
2023 Q1	$8.72K	Buy	+245	New	+$8.57K	﹤0.01%	302

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sageworth Trust's GSK Position: Q2 2023 in Review

Sageworth Trust sold out of GSK (GSK) in Q2 2023, closing a stake of 245 shares — an estimated $8.72K sold.

Sageworth Trust first reported a position in GSK in Q1 2023 and held it in 1 quarter. The position peaked at $8.72K in Q1 2023. 827 funds tracked by Wall St. Rank hold GSK as of Q2 2023.

Sageworth Trust reported no remaining GSK position as of Q2 2023 after selling out during the quarter.
Sageworth Trust sold 245 GSK shares in Q2 2023, an estimated $8.72K.
Sageworth Trust first reported a position in GSK in Q1 2023 and held it in 1 quarter.
Sageworth Trust's GSK position peaked at $8.72K in Q1 2023.
827 funds tracked by Wall St. Rank held GSK as of Q2 2023.

Based on Sageworth Trust's 13F filing for Q2 2023, filed 26 Jul 2023.